Literature DB >> 20515674

Anesthetic considerations in orthopedic patients with or without trauma.

Amandeep S Chohan1.   

Abstract

Anesthetic management of orthopedic patients could vary from normal routine management to more challenging critical management depending on the state in which the patient is presented. Multimodal pain management strategies incorporating opioids, which are the mainstay drugs for pain management, along with adjunctive drugs like local anesthetics (eg, lidocaine), dissociative anesthetics (eg, ketamine), and alpha-2 agonists (eg, dexmedetomidine), could improve overall patient comfort and help prevent establishment of chronic pain pathways. Also, use of local nerve blocks can prevent nociception right at the point of origin. Orthopedic patients with multiple organ traumas like head injuries, spinal injuries, pulmonary fat embolism, compartment syndrome, or thoracic injuries are high-risk patients in which any life-threatening organ pathology should be addressed before the patient is put under general anesthesia. Interactions of various drugs like antibiotics and neuromuscular blocking agents used in the perioperative period in orthopedic patients should warrant a careful consideration with respect to their interactions with each other and other anesthetic drugs used.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20515674     DOI: 10.1053/j.tcam.2010.01.002

Source DB:  PubMed          Journal:  Top Companion Anim Med        ISSN: 1946-9837


  2 in total

1.  Comparison of ketamine-xylazine and ketamine-dexmedetomidine anesthesia and intraperitoneal tolerance in rats.

Authors:  David Wellington; Igor Mikaelian; Laura Singer
Journal:  J Am Assoc Lab Anim Sci       Date:  2013-07       Impact factor: 1.232

2.  Anesthetic agent etiomidate induces apoptosis in N2a brain tumor cell line.

Authors:  Hong-Tao Chen; Jun Zhou; You-Ling Fan; Chun-Liang Lei; Bao-Jin Li; Li-Xin Fan; Li Xu; Ming Xu; Xiu-Qin Hu; Zhi-Ying Yu
Journal:  Mol Med Rep       Date:  2018-07-19       Impact factor: 2.952

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.